Skip to content
DataLookout
Menu

PREVENT-GUNCT05920343

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 7 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2026 to Jun 2028
    • Eligibility criteria expanded, about 19 words
    • Study sites: 1 to 3
    • Secondary endpoints: details revised at 3 of 4 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Feb 2026 to Oct 2026
    • Start date changed from estimate of Feb 2024 to Nov 4, 2024
    • Study sites: 0 to 1
    v4
  3. Notable Start date: Sep 2023 to Feb 2024
    • Primary and study completion dates: Sep 2025 to Feb 2026
    v3
  4. Notable Primary endpoint revised
    • Secondary endpoints revised (4)
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Feasibility of enrollment, assesed by the number of patients accrued per month
Timeframe: Enrollment

Secondary (4)

Adherence to the study intervention, assessed as the proportion of patients taking the study medication >80% of days taken during the study period,
Recruitment rate
VTE incidence
Bleeding incidence

Arms and interventions

RivaroxabanExperimental

Participants receiving study drug (Rivaroxaban)

ControlPlacebo comparator

Participants receiving matched placebo

Drugs: Rivaroxaban 10 MG

Other: Placebo control

Sites

3 sites in 1 country